YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment
YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
Featured Articles
Advanced Cardiac Therapeutics Studies Innovative Catheter System To Treat Arrythmias
ACT recently announced that the first patients have been enrolled in a CE Mark clinical trial of the safety and performance of the company’s TEMPASURE cardiac ablation catheter.
InSite Vision Is Developing Treatment For Common Eye Disease Blepharitis, For Which There Is Currently No Approved Treatment
InSite Vision has reached an agreement with the FDA on a Special Protocol Assessment for the design of a Phase 3 clinical trial of treatment in patients with blepharitis.
NeoStem To Drive Shareholder Value, Says Rodman & Renshaw
NeoStem said Thursday that equity research firm Rodman & Renshaw re-iterated the multi-faceted stem cell company’s market outperform rating, based on “multiple milestones to drive shareholder value”.
Ampio Pharmaceuticals Shows Promising Results In Treating The Most Common Male Sexual Dysfunction
Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction.
ImmunoCellular To Present Encouraging Phase 1 Study Results For Brain Tumour Treatment
ImmunoCellular Therapeutics will present positive results from a phase 1 clinical study on its ICT-107 therapy, a treatment for a type of brain tumor.
Rubigo Therapeutics Develops Early Assessment and Treatment for Skin Cancer
The fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by UV exposure or excessive sun burn.
Tianyin Pharmaceuticals Receives China’s SFDA Approval for Its Anti-Diabetic Drug Gliclazide
In 2010, there were 95 million cases of diabetes in China, of which, 52 million and 43 million were found in rural and urban areas, respectively.
Access Pharmaceuticals Inks Deal To Expand MuGard Distribution
Access Pharmaceuticals announced Tuesday it has signed an agreement with eMax Health Systems to expand the distribution of the company’s MuGard treatment.
Valeant Pharmaceuticals to acquire Lithuania’s Sanitas for $442m
Valeant Pharmaceuticals said Tuesday that it agreed to buy Lithuania-based generic drug company Sanitas for €314 million in cash.